- Home
- QXO vs EXEL Comparison
QXO vs EXEL Comparison
Compare QXO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXO | EXEL |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United States | United States |
| Employees | 7794 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 14.0B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | QXO | EXEL |
|---|---|---|
| Price | $15.18 | $52.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | $32.85 | ★ $46.50 |
| AVG Volume (30 Days) | ★ 23.5M | 2.3M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 1.60 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $70.27 | $13.61 |
| Revenue Next Year | $38.75 | $13.13 |
| P/E Ratio | ★ N/A | $71.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.18 | $33.76 |
| 52 Week High | $27.61 | $57.57 |
Technical Indicators
Market Signals| Indicator | QXO | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.00 | 41.45 |
| Support Level | $15.51 | $50.80 |
| Resistance Level | $15.68 | $52.84 |
| Average True Range (ATR) | 0.74 | 1.64 |
| MACD | 0.31 | -0.34 |
| Stochastic Oscillator | 85.81 | 10.61 |
Price Performance
Historical ComparisonAbout QXO QXO Inc.
QXO Inc is a publicly traded distributor of building products in North America. The company is executing its plan to become the tech-enabled leader in the around $800 billion building products distribution industry and generate outsized value for its shareholders. The group expects to achieve its target of nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.